Effectiveness of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine‐based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle‐invasive bladder cancer cases—Single‐center study in Japan

Abstract

ObjectivesTo compare the efficacy and safety of dose‐dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd‐MVAC) with gemcitabine‐based regimens for neoadjuvant chemotherapy (NAC) in muscle‐invasive bladder cancer (MIBC) patients treated in Japan.MethodsData for MIBC patients who received NAC‐dd‐MVAC followed by a radical cystectomy from June 2019 to May 2023 performed at our hospital were analyzed. For comparisons, data for MIBC patients who received NAC gemcitabine and cisplatin (GC) or gemcitabine and carboplatin (GCarbo) therapy between January 2010 and March 2019 were also obtained. Rates of ypT1N0 or less, progression‐free survival (PFS), overall survival (OS), and NAC adverse effects were compared between the GC/GCarbo and dd‐MVAC regimens.ResultsResults for 32 patients who received dd‐MVAC and 30 who received GC/GCarbo NAC therapy were analyzed. ypT1N0 or less was noted in 40.7% of the dd‐MVAC and 40.0% of the GC/GCarbo groups, while ypT0N0 rates were 25% and 10%, respectively, with no statistical differences noted. However, Kaplan–Meier analysis of the total cohort demonstrated that dd‐MVAC was associated with significantly better PFS and OS rates than GG/GCarbo (hazard ratios: 0.33, p = 0.0237, and 0.23, p = 0.0127, respectively). Propensity‐matched models also showed similar results for both PFS and OS. Adverse effects of dd‐MVAC were acceptable and the incidence of hematologic toxicity was lower as compared with GC/GCarbo therapy.ConclusionThe present study is the first to show that dd‐MVAC as NAC can provide better survival as compared with a gemcitabine‐based regimen for patients with MIBC treated in Japan.